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http://dx.doi.org/10.1016/j.kjms.201Abstract Increases in the generation of reactive oxygen species and decreases in antioxidant
enzyme activities with aging have been reported in the prostate, and are also observed in age-
related disorders such as atherosclerosis, Alzheimer’s disease, and cataracts. Several studies
have demonstrated that proteins are targets for reactive oxidants in cells, and that oxidized
proteins accumulate during aging, oxidative stress and in some pathological conditions.
However, only a limited number of studies have actually evaluated oxidative damage in rela-
tion to HDL-cholesterol-associated antioxidant enzyme activities or have assessed its relation-
ship with prostate cancer. In this study, we examined the effect of HDL-cholesterol-associated
antioxidant enzyme activities, paraoxonase1, arylesterase and new oxidative stress parame-
ters (total oxidant status, total antioxidant status [and oxidative stress index]) in newly-
diagnosed prostate cancer patients and healthy controls. There were no significant differences
in oxidative stress parameters and lipid parameters between prostate cancer patients and
controls, however, paraoxonase1 enzyme activity, and non-HDL-cholesterol levels were higher
in prostate cancer patients than controls. The results of this study were derived from a small
number of subjects, but might represent an important working hypothesis for further research
in a larger number of cases to clarify the role of paraoxonase1 overproduction on the prostate
and its clinical relevance.
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Prostate cancer (PCa) is the most common incidental
cancer and the second most common fatal cancer among
men, not only in USA but also in some developing countries
[1]. Like most cancers, both genetic and environmental
factors contribute to the pathogenesis of human PCa. PCa
incidence and mortality are known to vary greatly in
different geographic regions of the world. PCa mortality is
characteristically low in Asia compared to the high risks of
mortality in the USA and Western Europe [2]. In a recent
study of cancer risks among 44,788 pairs of twins in
Sweden, Denmark, and Finland, a statistically significant
effect of genotype was observed only for some 42% of PCa
cases, indicating that environment and lifestyle (including
diet) are likely to play a more dominant role than inheri-
tance in the development of most PCas [3].
How do the environment and lifestyle promote prostatic
carcinogenesis? It has been hypothesized that blood lipid
levels might be associated with PCa risk. During the past
decade, several findings have led to an augmented interest
in lipid profiles as predictors of PCa risk [4,5]. It is thought
that dietary fat intake might affect PCa risk. Most
population-based studies searching lipids and the risk of
PCa have focused on triglycerides (TG) and total cholesterol
(TC), but very few studies have investigated the functions
of HDL-cholesterol in patients with PCa.
A series of epidemiological and laboratory observations
suggest that oxidative stress, either from endogenous
sources such as inflammation and cellular metabolism, or
exogenous sources including ultraviolet light and environ-
mental toxins, contribute to the risk of prostate carcino-
genesis [6]. Oxidative stress and free radicals have been
associated with the increased risk of various cancers [7,8].
Aerobic organisms, within the course of evolution, have
developed complex xenobiotic enzyme systems for
protection against environmental genotoxins. The human
body has a number of endogenous free-radical scavenging
systems, including paraoxonase (PON), which principally
conjugate the intermediates to excretable hydrophilic
derivatives and bind to HDL-cholesterol, contributing to the
detoxification of organophosphorus compounds and carci-
nogenic lipid-soluble radicals from lipid peroxidation
[9,10]. PON1 is a liver-derived glycoprotein that is secreted
into the circulation. It is capable of hydrolyzing a diverse
array of substrates, including a variety of esters, lactones,
and man-made organophosphate compounds. PON1 enzyme
activity is affected by a number of factors such as genetic
mutations, smoking, stress, and high-fat diets. It has been
hypothesized that PON1 polymorphisms might contribute to
the increased risks of cancer associated with pollutants and
other environmental chemicals [11,12].
Small PCas have been mostly found in men aged 30e40
years old, while diagnoses of clinically-significant PCas are
typically found in men aged 60e70 years old [13]. Recent
scientific data have shown that basal and salt-stimulated
paraoxonase as well as arylesterase (ARE) activities were
significantly reduced in elderly compared to young individ-
uals [14]. Actually, the role of PON1 might be under-
estimated: the enzyme itself may determine the function of
HDL-cholesterol. Besides, hyper- and hypolipidemia, and theoxidation of lipoproteins are suggested to be fields in which
HDL-cholesterol and HDL-cholesterol-associated proteins
affect the course of lifestyle [15].
To the best of our knowledge, there is no study in the
literature that has measured the activity of PON 1, ARE and
oxidative balance in patients with PCa. The purpose of this
study was to identify oxidative stress in PCa patients, and
investigate whether the new generation biochemical
parameters or those that were previously known are asso-
ciated with the risk of incidental PCa.Materials and methods
Study population and clinical examinations
Twenty-three patients with newly-diagnosed PCa (mean
age 66.8  7.9 years) who had presented at the Urology
Outpatient Clinic of Antalya Education and Research
Hospital were prospectively included in the study. Forty
control individuals (mean age 62.3  10.7 years) were
enrolled for comparison. The control group consisted of
volunteers with a prostate-specific antigen (PSA) level in
the normal range and without any urological medical
history. The patients and controls were evaluated by the
same urologist. All individuals had a full physical exami-
nation and were asked to complete a general questionnaire
and gave informed consent before the onset of study. The
questions included: the age, social-economic status, origin
of ancestors, status of physical activity, smoking, alcohol
consumption, and detailed medical history. Blood pressure
was measured manually with a sphygmomanometer. Body
mass index was calculated as weight in kilograms divided by
height in meters squared. Hypertension was defined as
systolic blood pressure >140 mmHg and diastolic blood
pressure >90.
Those with a known past history of any major diseases
such as cardiac, renal, hepatic or endocrine disease were
excluded. None of the participants in the present study
were using drug medications including antihypertensive and
lipid-lowering agents, vitamins or antioxidant drugs.
Smokers and alcohol users were also excluded. The subjects
were locals with an average family income, favoring
common dietary habits, with a routine daily life. All men
were diagnosed with PCa after a pathologic review of
transrectal ultrasound-guided prostate needle core biop-
sies. Indications for biopsy included elevated PSA and an
abnormal digital rectal exam. Prostate biopsies were per-
formed utilizing a routine sextant pattern with at least 12
cores being obtained. After the pathology reports were
inspected, only patients with Gleason scores of 5e9 were
included in the study. According to the pathological
reports, Gleason score distributions of the diagnosed
carcinomas were as follows:
 5: 17.3% of patients;
 6: 47.0 of patients;
 7: 17.3% of patients;
 8: 8.6% of patients; and
 9: 8.6% of patients.
370 M. Eroglu et al.Any patients with a clinical or radiological suspicion of
metastatic PCa were excluded. Our aim was to compose as
homogenous a population as possible.
This study was performed in accordance with the ethical
standards set by the Declaration of Helsinki and was
approved by the local ethics committee.Analytical methods
Blood sample collection
Blood samples were obtained after an overnight fasting
state. Serum samples were then separated from the cells by
centrifugation at 3000 rpm for 10 minutes. Lipid parameters
and serum PSA levels were measured freshly. Remaining
serum portions were stored at e80C and used to analyze
PON1, ARE, total oxidant status (TOS) and TAS (total anti-
oxidant status).
Measurement of paraoxonase, arylesterase activities of
serum
PON1 and ARE activities were measured using commercially-
available kits (Relassay, Turkey). The fully-automated PON1
activity measurement method consists of two different
sequential reagents. The first reagent is an appropriate Tris
buffer, and it also contains calcium ions,which are a cofactor
of PON1 enzyme. A linear increase of the absorbance of
p-nitrophenol, produced from paraoxon, is followed at
kinetic measurement mode. Nonenzymatic hydrolysis of
paraoxon was subtracted from the total rate of hydrolysis.
The molar absorptivity of p-nitrophenol is 18.290 M1 cm1
and one unit of paraoxonase activity is equal to 1 mol of
paraoxon hydrolyzed per liter per minute at 37C [16].
Phenylacetate was used as a substrate to measure the
ARE activity. PON1, which is present in the sample,
hydrolyses phenylacetate to its products, which are phenol
and acetic acid. The produced phenol is colorimetrically
measured via oxidative coupling with 4-aminoantipyrine
and potassium ferricyanide. Nonenzymatic hydrolysis of
phenylacetate was subtracted from the total rate of
hydrolysis. The molar absorptivity of colored complex is
4000 M1 cm1 and one unit of arylesterase activity is equal
to 1 mmol of phenylacetate hydrolyzed per liter per minute
at 37C [17].
Measurement of the total antioxidant status of serum
The TAS of the serum was measured using a novel auto-
mated colorimetric measurement method developed by
Erel [18]. In the TAS method, antioxidants in the sample are
reduced from dark blue-green colored 2,20-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) radical to
a colorless, reduced ABTS form. The change of absorbance
at 660 nm is related to the total antioxidant level of the
sample. Using this method, the antioxidative effect of the
sample against the potent free radical reactions initiated
by the hydroxyl radical produced, is measured. The results
are expressed as micromolar trolox equivalent per liter.
Measurement of the total oxidant status of serum
The TOS of the serum was measured using a novel auto-
mated colorimetric measurement method developed by
Erel [19]. In the TOS method, oxidants present in thesample oxidize the ferrous ionechelator complex to ferric
ion. The ferric ion makes a colored complex with chro-
mogen in an acidic medium. The color intensity, which can
be measured spectrophotometrically, is related to the total
amount of oxidant molecules present in the sample. The
results are expressed in terms of micromolar hydrogen
peroxide equivalent per liter.
Oxidative stress index
The percentage ratio of TOS level to TAS level was accepted
as the oxidative stress index (OSI). For calculation, the
resulting unit of TAS was changed to millimoles per liter,
and the OSI value was calculated according to the following
formula:
OSI (arbitrary unit) Z TOS (micromolar hydrogen
peroxide equivalent per liter)/TAS (micromolar trolox
equivalent per liter).
Routine parameters
The levels of TG, TC, HDL-cholesterol, and LDL-cholesterol
were determined by using commercially-available assay kits
(Abbott Diagnostics, Illinois, USA) with an autoanalyzer
(Architect c16000, Abbott Diagnostics, Illinois, USA). Non-
HDL-cholesterol was calculated as total cholesterol minus
HDL-cholesterol. Serum PSA levels were determined by
using commercially-available assay kits (Beckmann Access,
Krefeld, Germany) with an autoanalyzer (DXI 800, Beck-
mann Coulter, Krefeld, Germany).
Statistical analysis
Statistical analyses were carried out using the MedCalc
statistical software (MedCalc, Mariakerke, Belgium). The
results were expressed as mean  standard deviation. The
significance of the differences between groups was deter-
mined by the Student unpaired t test and the Man-
neWhitney U-test. The Pearson correlation coefficient was
used to test the strength of any associations between
different variables. Values of p < 0.05 were accepted as
significant.Results
The clinical data from patients and age-matched controls
are summarized in Table 1. The means of the body mass
index of the groups did not differ significantly. Nearly all of
the cancer patients reported unintentional weight loss, so
the finding was thought to be due to the cancer itself rather
than lifestyle. When the groups were compared according
to lipid parameters, non-HDL-cholesterol was higher in PCa
patients compared to the controls. Of interest, TC, TG, and
LDL-cholesterol levels did not differ significantly, suggest-
ing the superiority of clinical use of non-HDL-cholesterol as
a parameter. The PSA levels of PCa patients were higher
than controls, as expected (Table 1).
In oxidant/antioxidant parameters, the only
statistically-significant parameter was PON1 enzyme
activity, which was higher in PCa patients compared to
controls (p < 0.01). ARE enzyme activity, TAS, and TOS did
not show any significant difference. A striking finding was
the p value of ARE enzyme activity (p Z 0.94), demon-
strating very close enzyme activity in both groups (Table 2).
Table 1 Clinical data from patients and age-matched controls. The groups’ body mass index means did not differ significantly.
Non-HDL-cholesterol was higher in prostate cancer patients compared to the controls. The prostate-specific antigen levels of
prostate cancer patients were higher than controls, as expected.
Parameter (mean  SD)/(median) (interquartile range) Prostate cancer (n Z 23) Control (n Z 40) p-value
Age, mean  SD 66.8  7.9 62.3  10.7 0.08
Body mass index (kg/m2), mean  SD 26.6  4.3 26.7  2.9 0.91
Family history of prostate cancer (n) 8 (34.7%) d 0.92
Total cholesterol (mg/dL) 208.4  33.8 197.0  43.2 0.28
Triglyceride (mg/dL) 148.9  74.6 165.9  76.3 0.40
HDL-cholesterol (mg/dL) 45.5  11.4 41.7  9.9 0.17
LDL-cholesterol (mg/dL) 130.4  27.9 124.0  36.7 0.48
Non-HDL-cholesterol (mg/dL) 162.9  31.5 155.3  41.5 <0.01
Prostate-specific antigen (ng/mL) 7.78 (6.5e21.2) 1.41 (1.1e2.1) <0.0001
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between PON1, ARE, TAS and TOS in the PCa group. A
negative correlation between HDL-cholesterol and TOS,
HDL-cholesterol and OSI was found (Fig. 1).Discussion
The results of this study suggest that PON1 levels may
influence the risk of PCa. Frehman et al. reported that
PON1 deficiency in mice was associated with decreased
macrophage scavenger receptor class B member 1 (SR-BI)
expression, decreased cellular HDL-cholesterol binding,
and consequently the loss of HDL-cholesterol-mediated
cytoprotection against apoptosis [20]. Sekine et al. have
reported that HDL-cholesterol leads to increased prolifer-
ation and migration of PCa cells [21]. In theory, PON1
activity may influence carcinogenesis not only by limiting
exposure to toxic organophosphate metabolites, but also by
influencing the putative effects of pesticides on immune
function and oxidative stress. PON1 can also hydrolyze N-
acyl-homoserine lactones, which are quorum-sensing
signals of pathogenic bacteria [22]. PON1 variants are
under investigation because their activity may limit the
damage caused by bacterial endotoxins, prevent lipid
oxidation, and possibly decrease the risk of inflammation-
related diseases such as atherosclerosis and cancer
[23e25].
PON1 Arg192Gln and Met55Leu variants have been associ-
atedwith substrate-dependent effects on activity. Recently-
discovered e108T and e162A promoter variants have been
shown to be associated with increased activity [26]. This is
a gene encoding the human serum paraoxonase enzyme
consistently implicated in lipid metabolism and in theTable 2 The comparison of various parameters in prostate ca
parameter differing between groups. PON1 was higher in prostat
Parameter (mean  SD)/(median) (interquartile range) Pro
PON1 (U/L)
Arylesterase (kU/L)
Total antioxidant status (nmol Troloks/L)
Total oxidant status (mmol H2O2 Equiv./L)
Oxidative stress indexelimination of carcinogenic lipid-soluble radicals. Moreover,
PON1 genotypes significantly affect the susceptibility of LDL-
and HDL-cholesterol to lipid peroxidation [27].
Measurement of TAS and TOS are valuable, as they
provide information about the “totals” of oxidants and
antioxidants not yet recognized or not easily measured.
However, they present unrefined, vague results for the
same reason, making it crucial to further examine partic-
ular enzyme activities. Accordingly, we measured PON1 and
ARE activities, two enzymes particularly important in
antioxidative defense. We did not find any significant
differences in TAS and TOS. Worryingly, PON1 enzyme
activity was significantly increased in PCa patients, while
ARE enzyme activity was similar in both groups, in spite of
the significant difference expected. The discrepancy
clearly underscores the fact that PON1 is a multi-facetted
enzyme with functional sites specialized for distinctly
separate activities [28].
Kok et al. reported serum TC, HDL-cholesterol, LDL-
cholesterol and TG as potential risk factors for PCa using
multivariable Cox proportional hazard regression models.
Higher TC and higher LDL-cholesterol were significantly
associated with an increased risk of PCa (hazard ratios [HR]
and 95% confidence interval [CI] per mmol l1 were 1.39
(95% CI 1.03e1.88) and 1.42 (95% CI 1.00e2.02), respec-
tively) [29]. A recent study showed that HDL-cholesterol
increased serine 727 phosphorylation of Stat3, S1P, and
that rHDL-S1P, also induced the phosphorylation [30].
However, the exact roles of different cholesterol fractions
on PCa aggressiveness should be further evaluated.
The number of subjects was a major limitation of this
study. However, the selected patients were free from any
diseases requiring medication, and from smoking and
alcohol consumption, that might have been confoundingncer patients and controls, showing that PON1 was the only
e cancer patients.
state cancer (n Z 23) Control (n Z 40) p-value
103.8  64.7 76.5  46.5 <0.01
136.7  59.9 135.5  65.7 0.9419
1.31  0.42 1.35  0.29 0.4639
4.02 (3.4e5.4) 4.76 (3.9e6.1) 0.1929
372 (338e453) 353 (294e424) 0.2962
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Figure 1. Graphics of significant correlations in prostate cancer patients. (A) Arylesterase (ARE) and total antioxidant status
(r Z 0.58, p Z 0.004); B) ARE and total oxidant status (r Z 0.45, p Z 0.03); C) ARE and paraoxonase (r Z 0.45, p Z 0.03);
D) triglycerides and oxidative stress index (rZ 0.42, pZ 0.04); E) total oxidant status and HDL-cholesterol (rZ 0.49, pZ 0.01);
F) oxidative stress index and HDL-cholesterol (r Z 0.48, p Z 0.01).
372 M. Eroglu et al.factors. We should appreciate the difficulty of composing
groups of patients and controls in the relevant age group
fulfilling the aforementioned criteria. After all, we strongly
believe in the specificity of our findings. This study should
therefore be recognized as having an impact on new ones
with larger groups of patients.
There are great deals of data in the literature indicating
that oxidative stress is involved in the pathomechanism of
many diseases, including cancer. Lipid parameters, and
particularly HDL-cholesterol, have been the ultimate focus
of studies so far. However, our recent understanding of the
“functionality of HDL-cholesterol” has made the measure-
ments of the quality of HDL-cholesterol the primary target
instead of traditional measurements of the quantity of HDL-
cholesterol [31]. Unsurprisingly, an exuberant welcome
awaits the therapeutics aiming to decrease or avoid
oxidative damage in the human body. PON1 is the most
promising actor in this area of research. Against such
a background of aberrant optimism, rare studies like ours
present clues that PON1-targeted medications bare
unwanted consequences, such as promoting carcinogenesis.
Oxidative stress and antioxidative therapies should be
handled with extra care in cancer, due to the potential
diversities in patient behavior.
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